10-Q/A: Cardiff Lexington Q2/2024 Restatement Reveals Revenue Drop

Cardiff Lexington Corporation files an amended Q2 2024 report, restating financials due to reclassification of non-cash interest expense and a significant reduction in healthcare revenue from accelerated settlements.

Summary

• The company filed an Amendment No. 2 on Form 10-Q for the period ended June 30, 2024, to correct an error in the classification of non-cash interest expense in the condensed consolidated statements of cash flows.
• The restatement reclassified $845,427 of non-cash interest accrual adjustments from financing activities to operating activities for the six months ended June 30, 2024.
• The restatement also corrected the accounting for its allowance for credit losses and credit loss expense, reclassifying $1,199,155 of credit loss expense to net revenue as variable consideration for the six months ended June 30, 2024.
• Net loss for the three months ended June 30, 2024, was $(131,585), a significant decrease from net income of $816,078 for the same period in 2023.
• Net loss for the six months ended June 30, 2024, was $(414,689), compared to net income of $800,087 for the same period in 2023.
• Total revenue decreased by 56.26% to $1,471,643 for the three months ended June 30, 2024, from $3,364,506 in the prior year period.
• Total revenue decreased by 37.51% to $3,793,775 for the six months ended June 30, 2024, from $6,070,905 in the prior year period.
• The decrease in revenue is primarily attributed to a shift in service mix (less surgical, more pain management) and efforts to accelerate cash settlements by accepting lower realization rates.
• The average settlement realization rate for gross billed charges in the healthcare segment decreased from a historical 49% to 42.3% during the six months ended June 30, 2024.
• The company reported an accumulated deficit of $69,576,612 as of June 30, 2024, and has sustained recurring operating losses, raising substantial doubt about its ability to continue as a going concern.
• Cash and cash equivalents increased to $3,196,795 as of June 30, 2024, from $866,943 at December 31, 2023, primarily due to proceeds from a line of credit.

Sentiment

Score: 2

Explanation: The company exhibits severe financial distress, marked by a dramatic decline in revenue, a shift from net income to significant net losses, and a substantial accumulated deficit. The explicit "going concern" warning, coupled with the need for significant external capital to merely sustain operations and execute its business plan, highlights extreme financial risk. The strategy of accepting lower settlement rates to accelerate cash flow further erodes profitability. Material weaknesses in internal controls add to the negative sentiment.

Positives

• Cash and cash equivalents increased significantly to $3,196,795 as of June 30, 2024, from $866,943 at December 31, 2023.
• The company recorded a gain on debt refinance and forgiveness of $78,834 for the three months ended June 30, 2024.
• The maximum advance amount on the revolving purchase and security agreement (line of credit) was increased to $11,000,000 as of June 11, 2024.
• Successful settlement of certain convertible notes and Series R preferred stock into a new fixed amount promissory note and Series Y senior convertible preferred stock, reducing complex debt structures.

Negatives

• The company experienced a significant decline in revenue, with a 56.26% decrease for Q2 2024 and a 37.51% decrease for H1 2024 compared to the prior year periods.
• A shift from net income to net loss occurred, with a net loss of $(131,585) in Q2 2024 (vs. $816,078 net income in Q2 2023) and $(414,689) in H1 2024 (vs. $800,087 net income in H1 2023).
• Gross profit margin decreased substantially from 67.85% to 46.11% in Q2 2024 and from 66.43% to 54.10% in H1 2024.
• The average settlement realization rate for healthcare gross billed charges decreased from a historical 49% to 42.3% in H1 2024, resulting in a $1,199,155 reduction in net revenue.
• Selling, general and administrative expenses increased by 57.50% in Q2 2024 and 11.08% in H1 2024.
• The company has sustained recurring operating losses since inception and has an accumulated deficit of $69,576,612 as of June 30, 2024, raising substantial doubt about its ability to continue as a going concern.
• Net cash used in operating activities from continuing operations increased to $(1,135,300) for H1 2024 from $(260,466) for H1 2023.
• Material weaknesses in internal control over financial reporting were identified and are still in the process of remediation.
• The company is delinquent in paying certain property taxes, with a balance of $1,649 as of June 30, 2024.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to sustained recurring operating losses and a significant accumulated deficit.
• Dependence on additional cash infusions and new financing/equity raises for continued operations and to execute its business plan and acquisition strategy.
• No assurance that sufficient capital from debt or equity transactions will be available in necessary amounts or on acceptable terms.
• The sale of additional equity securities could result in significant dilution to existing stockholders.
• Incurrence of new indebtedness would lead to increased debt service obligations and potentially restrictive operating and financial covenants.
• No guarantee that the company will be able to acquire additional businesses under favorable terms.
• Operational plans may need to be curtailed if sufficient funds are not raised.
• Need to implement cost reductions if overall company expenses increase, potentially impacting operations.
• No assurance that the company will be able to operate profitably on a consistent basis, or at all, in the future.
• Risk of cessation of operations if sufficient funds are not raised.
• Inherent uncertainties and potential adverse results from various lawsuits and legal proceedings that may arise in the ordinary course of business.
• Material weaknesses in internal control over financial reporting, which are still being remediated, could adversely affect the company's ability to record, process, summarize, and report financial information reliably.
• The remedial measures for internal control weaknesses may not fully address the identified issues, and new material weaknesses may be identified in the future.
• Fluctuations in the settlement realization rate for healthcare accounts receivable could continue to negatively impact revenue and cash flow.

Future Outlook

The company believes its current working capital and expected additional financing should be sufficient to fund operations and satisfy obligations for at least one year. However, additional funds ranging from $4 million to $10 million from new financing and/or future equity raises are required for continued operations and to execute its business plan, including new acquisitions. The company expects the trend of lower settlement realization rates for healthcare receivables to continue in the short term as it prioritizes accelerating cash settlements for operational cash flow.

Management Comments

• "Management is in continuous discussions with prospective investors and believes the raising of capital will allow the Company to fund its cash flow shortfalls and pursue new acquisitions."
• "We expect this trend [lower settlement realization rate] to continue in the short term as we work to settle our accounts receivables more quickly to generate cash flow for operations."
• "Management has invested years working to develop a new and exciting housing development in Salmon, Idaho and plans to enter into a joint venture agreement with a developer for this planned concept development."

Industry Context

The company operates as an acquisition holding company primarily focused on the healthcare industry through its subsidiary Nova Ortho and Spine, LLC, which provides lien-based orthopedic and pain management services to an uninsured market. This niche relies on letters of protection and insurance settlements, differing from traditional healthcare models. The real estate segment, Edge View Properties, Inc., holds land for residential development. The significant decline in healthcare revenue, coupled with a strategic shift to accept lower settlement rates for faster cash flow, suggests a challenging operating environment or an urgent need for liquidity within its healthcare segment. The divestiture of the Platinum Tax Defenders financial services business indicates a streamlining of focus towards its core healthcare and real estate assets.

Comparison to Industry Standards

• The company's healthcare segment operates in a niche lien-based medical industry, which historically boasts a high collection rate (99%) due to letters of protection, a model distinct from typical fee-for-service or insurance-reimbursement healthcare providers.
• The reduction in the average settlement realization rate for healthcare services from a historical 49% to 42.3% indicates a significant concession on gross billed charges, which, while common in personal injury or lien-based practices, suggests increased pressure or a strategic pivot to prioritize liquidity over maximizing revenue per case.
• The accumulated deficit of $69,576,612 and recurring operating losses place the company in a financially distressed position, far below the profitability and stability benchmarks of healthy, publicly traded healthcare or real estate development companies.
• The explicit 'going concern' warning and the stated need for $4 million to $10 million in additional capital for operations and acquisitions highlight a severe liquidity crunch and a high-risk investment profile, contrasting sharply with financially robust industry peers that generate sufficient cash flow internally or access capital markets on more favorable terms.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that it believes will have a material adverse effect on its business, financial condition, or operating results.

Related Party Transactions

• Amounts due from previous owners of Edge View (who are current managers) totaled $4,979 as of June 30, 2024, due on demand and non-interest bearing.
• The company owed $0 to the Chairman of the Board as of June 30, 2024, having paid $120,997 during the six months ended June 30, 2024.
• A twelve-month convertible promissory note in the principal amount of $5,000 was issued to the CEO on August 25, 2023, for operating expenses, bearing 10% interest per annum.
• Outstanding accrued compensation to the Chief Executive Officer was $2,115,500 as of June 30, 2024 (50% cash, 50% accrued through Dec 31, 2023, now all cash).
• Outstanding accrued compensation to the Chairman of the Board was $2,220,500 as of June 30, 2024 (50% cash, 50% accrued through April 30, 2024, now all cash).
• Issued 62,500 shares of Series I preferred stock to Daniel R. Thompson (Chairman) and Alex Cunningham (CEO) for $250,000 bonus compensation in January 2024.
• Issued 5,000 shares of Series I preferred stock to Matthew Shafer (CFO) for $20,000 in January 2024.
• Issued 2,500 shares of Series I preferred stock to Zia Choe (Chief Accounting Officer) for $10,000 in January 2024.
• Issued 30,000 shares of common stock to three board members for $195,000 in March 2024.
• Issued 3,150 shares of Series B preferred stock to Zia Choe (Interim Chief Financial Officer) for $25,000 in May 2023.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity raises and the conversion of various preferred stock series and convertible notes into common stock.
• Shareholders are negatively impacted by the company's recurring operating losses, substantial accumulated deficit, and the explicit 'going concern' warning, which signals high investment risk.
• Employees, particularly management, receive substantial compensation, including accrued amounts and stock-based payments, indicating a commitment to key personnel despite financial challenges.
• Creditors are exposed to the company's high debt levels, including a large line of credit and convertible notes, though some debt has been restructured through settlement agreements.
• Customers (patients) in the healthcare segment may experience indirect impacts from the company's strategy of accepting lower settlement rates to accelerate cash flow, which could influence service delivery or billing practices over time, though the filing does not specify direct customer impact.

Next Steps

• Continue efforts to remediate identified material weaknesses in internal control over financial reporting.
• Evaluate updated internal controls design and determine their effectiveness during 2024.
• Complete a planned underwritten public offering to raise necessary capital.
• Continue to evaluate the estimate of settlement realization rates for healthcare services on a monthly basis.
• Enter into a joint venture agreement with a developer for the planned housing development in Salmon, Idaho.

Key Dates

Recommendation

The company exhibits severe financial distress, marked by a dramatic decline in revenue, a shift from net income to significant net losses, and a substantial accumulated deficit. The explicit "going concern" warning, coupled with the need for significant external capital to merely sustain operations and execute its business plan, highlights extreme financial risk. The strategy of accepting lower settlement rates to accelerate cash flow indicates a desperate need for liquidity at the expense of profitability. Furthermore, identified material weaknesses in internal controls raise concerns about financial reporting reliability. Given these compounding negative factors and the high probability of further dilution or operational curtailment, the stock presents a very high risk profile with little apparent upside in the near term.

Keywords

Healthcare, Real Estate, Acquisition Holding Company, SEC Filing, 10-Q/A, Financial Restatement, Convertible Notes, Preferred Stock, Liquidity, Going Concern, Nova Ortho and Spine, Edge View Properties, Corporate Governance, Risk Management, Financial Reporting